Aug 30 2017
Montevideo, Uruguay—GBT-Grupo Biotoscana (B3: GBIO33), a leading specialty pharmaceutical company in Latin America, today announced that it has expanded its partnership with Gilead Sciences (Nasdaq: GILD) in HCV in Brazil. Under a previous agreement, Gilead Sciences had granted distribution rights to GBT-Grupo Biotoscana (GBT), for SOVALDIÒ (400 mg sofosbuvir). Under the new agreement, the parties have arranged to extend the term for SOVALDIÒ and include the distribution of HARVONIÒ (90 mg ledipasvir / 400 mg sofosbuvir). GBT maintains all its rights and obligations under prior agreement. This announcement confirms the intensification of the
years-long partnership between GBT and Gilead Sciences.
“GBT is very enthusiastic to be able to expand this existing partnership and broaden the HCV treatment options by adding leading brand HARVONIÒ to better serve more patients and doctors with this serious infectious disease, explains Mariano García-Valiño, CEO of GBT.
HARVONIÒ is not an approved drug in Brazil yet, where local health authorities are in the process of reviewing the health registration dossier filed by Gilead Sciences.
Gilead Sciences will continue to be responsible for supplying these treatment options directly to the Brazilian Ministry of Health.
About GBT-Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fastgrowing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com
SOVALDIÒ (400 mg sofosbuvir). is a prescription medicine used with other antiviral medicines to treat chronic (lasting a long time) hepatitis C genotype 1, 2, 3, or 4 infections in adults. It is not known if SOVALDI is safe and effective in children under 18 years of age. Brazil full prescribing information for SOVALDIÒ is available here.
HARVONIÒ (90 mg ledipasvir / 400 mg sofosbuvir) is a prescription medicine used with or without ribavirin to treat chronic (lasting a long time) hepatitis C genotype 1, 4, 5 or 6 infections. It is not known if HARVONI is safe and effective in children under 18 years of age. HARVONIÒ is under review of Brazilian health authorities and it is not yet an approved drug in this territory.
SOVALDIÒ and HARVONIÒ are registered trademarks of Gilead Sciences, Inc. or its related companies.
Forward-Looking Statements (GBT)
This release includes forward-looking statements concerning a transaction between Gilead Sciences and GBT-Grupo Biotoscana, including expectations regarding the applicability of predictions to the commercialization of certain products. GBT-Grupo Biotoscana disclaims any obligation to update any forward-looking statement, except as required by applicable law.
GBT - Grupo Biotoscana
Tel.: +55 11 5090 5923